RxDoctor Payments Data

Ravikumar Peddireddy, MD

Internal Medicine · Flint, MINPI 1710989546

Payments from drug & device makers

$1,713in general payments, 2019–2025

Across 119 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$394
  • GSK$227
  • Amgen$150
  • Biohaven Pharmaceuticals, Inc.$129
  • Novartis$124
  • Bayer$77
  • plus $613 from 20 others

What the payments were for

  • Food & beverage$1,68398%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,713 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$221,355
Medicare patients
461
Services billed
4,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$383,938
JanuviaSitagliptin Phosphate120$134,873
OzempicSemaglutide57$97,203
XareltoRivaroxaban57$79,116
EntrestoSacubitril/Valsartan37$62,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$59,828
JardianceEmpagliflozin48$59,360
TrulicityDulaglutide46$52,278
RybelsusSemaglutide28$34,451
Tresiba Flextouch U-100Insulin Degludec35$30,952
Tresiba Flextouch U-200Insulin Degludec12$27,826
Lantus SolostarInsulin Glargine,hum.Rec.Anlog128$26,872
MounjaroTirzepatide21$20,383
Atorvastatin Calcium1,106$18,376
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate74$16,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$383,938310 claims
MerckJanuvia, Dulera$12$145,218143 claims
Novo NordiskOzempic, Rybelsus$394$131,65485 claims
Lilly USA, LLCTrulicity, Mounjaro$29$72,66267 claims
NovartisEntresto$124$62,24237 claims
GSKTrelegy Ellipta$227$59,82862 claims
Sanofi-aventis U.S. LLCLantus$65$10,32649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →